Impact of tuberculosis on HIV disease progression in persons with well-documented time of HIV seroconversion

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 2, 2003, Pages 184-190

  Del Amo, Julia ^a   Porter, K ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

AIDS; Disease progression; HIV; Seroconveners; Tuberculosis

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SEROCONVERSION; TUBERCULOSIS; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0038078715     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200306010-00011     Document Type: Article

References (38)

1. Report on the global HIV/AIDS epidemic 2002. Available at: http://www.unaids.org.
2. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-686.
3. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143-152.
4. Styblo K. Epidemiology of tuberculosis. In: Royal Netherlands Tuberculosis Association (KNCV) selected papers. 1991.
5. De Cock KM, Soro B, Coulibaly IM, et al. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA. 1992;268:1581-1587.
6. Collaborative Group on AIDS Incubation and HIV Survival. Time from HIV-1 seroconversion to AIDS and death before the widespread use of highly active anti-retroviral therapy: a collaborative re-analysis. Lancet. 2000;335:1131-1137.
7. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science. 1996;273:1856-1862.
8. Hendel H, Caillat-Zucman S, Lebuanec H, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol. 1999;162:6942-6946.
9. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405-411.
10. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;17:1497-1503.
11. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV infection. Lancet. 2000;355:1158-1159.
12. Del Amo J, Malin AS, Pozniak A, et al. Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. AIDS. 1999;13:1151-1158.
13. Wallis RS, Vjecha M, Amir Tahmasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1); enhanced cytokine expression and elevated beta 2 microglobulin in HIV-1 associated tuberculosis. J Infect Dis. 1990;167:43-48.
14. Garrait V, Cadranel J, Esvant H, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J Immunol. 1997;159:2824-2830.
15. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996;157:1271-1278.
16. Hsieh SM, Hung CC, Chen MY, et al. Dynamics of plasma cytokine levels in patients with advanced HIV infection and active tuberculosis: implications for early recognition of patients with poor response to anti-tuberculosis treatment. AIDS. 1999;13:935941.
17. Lawn S, Shattock R, Acheampong J, et al. Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. AIDS. 1999;13:2231-2237.
18. Collins KR, Mayanja-Kizza H, Sullivan BA, et al. Greater diversity of HIV-1 quasispecies in HIV-infected individuals with active tuberculosis. J Acquir Immune Defic Syndr. 2000;15:408-417.
19. Toossi Z, Johnson JL, Kanost RA, et al. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr. 2001;28:1-8.
20. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123:233-238.
21. Mayanja-Kizza H, Wajja A, Wu M, et al. Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis. 2001;183:1801-1804.
22. Lederman MM, Georges DL, Kusner DJ, et al. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1994;7:727-733.
23. Whalen C, Horsburgh R, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Crit Care Med. 1995;151:129-135.
24. Perneger TV, Sudre P, Lundgren JD, et al., for the AIDS in Europe Study Group. Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. BMJ. 1995;311:1468-1471.
25. Leroy V, Salmi RL, Dupon M, et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease. A cohort study in Bordeaux, France 1988-1994. Am J Epidemiol. 1997;45:293-300.
26. Whalen C, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS. 2000;14:1219-1228.
27. Badri M, Ehrlich R, Wood R, et al. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis. 2001;5:225-232.
28. Mocroft AJ, Lundgren JD, d'Armino Monforte A, et al. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol. 1997;26:400-407.
29. Petruckevitch A, Del Amo J, Phillips AN, et al. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS. 1998;12:1007-1013.
30. Day JH, Grant AD, Fielding KL, et al. Does tuberculosis increase HIV viral load? Presented at the XIV International AIDS Conference, July 2002.
31. Eberly LE, Ohman PA, Neaton JD, et al. Kaposi's sarcoma and central nervous system disease: a real association or an artifact of the control group? Terry Beim Community Programs for Clinical Research on AIDS. AIDS. 2000;14:995-1000.
32. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in persons with known duration of HIV infection in Europe. HIV Med. 2000;1:224-231.
33. Mocroft AJ, Johnson MA, Sabin CA, et al. Clinical staging system for AIDS patients. Lancet. 1995;346:12-17.
34. Therneau TM, Grambsch PM. Modelling survival data: extending the Cox model. New York: Springer-Verlag; 2000:69-73.
35. Mocroft A, Sabin C, Phillips AN. Impact of Kaposi's sarcoma on HIV disease progression. AIDS. 1999;13:286.
36. Donovan RM, Bush CE, Markowitz NP, et al. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis. 1996;174:401-403.
37. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-1230.
38. Bentwich Z, Maartens G, Torten D, et al. Concurrent infections and HIV pathogenesis. AIDS. 2000;14:2071-2081.